Heska (NASDAQ:HSKA) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Heska (NASDAQ:HSKA – Get Rating) in a research note issued to investors on Thursday morning. The brokerage issued a hold rating on the medical research company’s stock.

HSKA has been the topic of several other reports. Alliance Global Partners upped their price target on shares of Heska from $119.00 to $129.00 in a report on Wednesday, March 1st. Piper Sandler decreased their price objective on shares of Heska from $165.00 to $150.00 in a report on Thursday, March 2nd. Finally, Morgan Stanley lowered shares of Heska from an equal weight rating to an underweight rating and set a $58.00 price objective for the company. in a report on Friday, January 6th. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. According to MarketBeat, Heska has an average rating of Hold and a consensus target price of $121.75.

Heska Stock Performance

Shares of HSKA traded down $1.21 during mid-day trading on Thursday, reaching $88.50. 249,295 shares of the stock traded hands, compared to its average volume of 95,586. The stock has a fifty day simple moving average of $83.64 and a 200 day simple moving average of $75.53. Heska has a 12-month low of $57.83 and a 12-month high of $151.43. The company has a current ratio of 6.70, a quick ratio of 5.18 and a debt-to-equity ratio of 0.23.

Insider Activity

In other Heska news, CEO Kevin S. Wilson purchased 11,018 shares of the firm’s stock in a transaction dated Friday, January 6th. The stock was acquired at an average cost of $58.62 per share, with a total value of $645,875.16. Following the acquisition, the chief executive officer now owns 167,072 shares of the company’s stock, valued at approximately $9,793,760.64. The purchase was disclosed in a filing with the SEC, which is accessible through this link. In other Heska news, CEO Kevin S. Wilson purchased 3,440 shares of the firm’s stock in a transaction dated Thursday, December 22nd. The stock was acquired at an average cost of $59.64 per share, with a total value of $205,161.60. Following the acquisition, the chief executive officer now owns 156,054 shares of the company’s stock, valued at approximately $9,307,060.56. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Kevin S. Wilson purchased 11,018 shares of the firm’s stock in a transaction dated Friday, January 6th. The stock was acquired at an average cost of $58.62 per share, with a total value of $645,875.16. Following the completion of the acquisition, the chief executive officer now directly owns 167,072 shares in the company, valued at approximately $9,793,760.64. The disclosure for this purchase can be found here. Company insiders own 11.00% of the company’s stock.

Institutional Trading of Heska

Several hedge funds have recently bought and sold shares of the company. Synovus Financial Corp lifted its position in Heska by 2.7% in the 2nd quarter. Synovus Financial Corp now owns 5,199 shares of the medical research company’s stock valued at $493,000 after purchasing an additional 138 shares during the last quarter. Wrapmanager Inc. increased its position in shares of Heska by 3.9% in the fourth quarter. Wrapmanager Inc. now owns 4,297 shares of the medical research company’s stock worth $267,000 after acquiring an additional 162 shares in the last quarter. Texas Permanent School Fund increased its position in shares of Heska by 2.7% in the second quarter. Texas Permanent School Fund now owns 7,800 shares of the medical research company’s stock worth $737,000 after acquiring an additional 206 shares in the last quarter. Mutual of America Capital Management LLC grew its position in Heska by 11.7% during the third quarter. Mutual of America Capital Management LLC now owns 2,024 shares of the medical research company’s stock valued at $148,000 after purchasing an additional 212 shares in the last quarter. Finally, Signaturefd LLC grew its position in Heska by 146.3% during the fourth quarter. Signaturefd LLC now owns 399 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 237 shares in the last quarter. 99.01% of the stock is currently owned by institutional investors.

Heska Company Profile

(Get Rating)

Heska Corp. engages in the provision of veterinary and animal health diagnostic, and specialty products. It operates through the North America and International segments. The North America segment includes the United States, Canada, and Mexico. The International segment involves Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland.